Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-19 · accession 0001799191-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-20 | 2025-03-19 | STLN | Virnich Daniel | CEO | D - Sale to Iss | $0.89 | -10.3K | 701.7K | -1% | -$9,132 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-03-19 | D | D | 10,261 | $0.89 | 701,723 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. |